MedTrace Logo

Cardiotoxicity and Other Late Effects After Radiotherapy and Immuno-chemoTherapy in Non-Hodgkin lYmphoma

NCT07041827 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 217

Last updated 2025-06-27

No results posted yet for this study

Summary

Survivors of non-Hodgkin lymphoma and a control group will be screened for (sub)clinical cardiovascular disease, to assess the influence of contemporary treatments on risk and burden of (sub)clinical cardiovascular disease and their influence on survival.

Conditions

Interventions

DIAGNOSTIC_TEST

Cardiovascular assessment

A cardiovascular assessment will be performed to screen for (sub)clinical cardiovascular diseases and to compare the prevalences in survivors of non-Hodgkin lymphoma and a control group.

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    collaborator OTHER

  • The Netherlands Cancer Institute

    lead OTHER

Principal Investigators

  • Michael Schaapveld, PhD · The Netherlands Cancer Institute

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-02-01
Primary Completion
2022-10-01
Completion
2023-02-01

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07041827 on ClinicalTrials.gov